Extension of Time to File SOU

INGREZZA

Neurocrine Biosciences, Inc.

Request for Extension of Time to File a Statement of Use

PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88155208
LAW OFFICE ASSIGNED LAW OFFICE 113
MARK SECTION
MARK http://uspto.report/TM/88155208/mark.png (stylized and/or with design)
STANDARD CHARACTERS NO
USPTO-GENERATED IMAGE NO
OWNER SECTION (current)
NAME Neurocrine Biosciences, Inc.
MAILING ADDRESS 12780 El Camino Real
CITY San Diego
STATE California
ZIP/POSTAL CODE 92130
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
OWNER SECTION (proposed)
NAME Neurocrine Biosciences, Inc.
MAILING ADDRESS 12780 El Camino Real
CITY San Diego
STATE California
ZIP/POSTAL CODE 92130
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME B. Brett Heavner
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE docketing@finnegan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
CORRESPONDENCE INFORMATION (proposed)
NAME B. Brett Heavner
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE docketing@finnegan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
DOCKET/REFERENCE NUMBER 14640.1002
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations for human use for schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and Tourette syndrome, movement disorders, namely, Myoclonus, Huntington's chorea, Levodopa-induced dyskinesia, tardive dyskinesia, dystonia, and tics; Pharmaceutical preparations for the treatment of neurological, central nervous system, and movement diseases and disorders; Pharmaceutical preparations for the treatment of tardive dyskinesia
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 3
ONGOING EFFORT product or service research or development
ALLOWANCE MAIL DATE 11/12/2019
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT [EXTENSION FEE] 125
TOTAL AMOUNT 125
SIGNATURE SECTION
SIGNATURE /David L. Bradfute/
SIGNATORY'S NAME David L. Bradfute, PhD, JD
SIGNATORY'S POSITION Vice President & Head, Intellectual Property
DATE SIGNED 05/07/2021
SIGNATORY'S PHONE NUMBER 202-408-4000 (Applicant's attorney)
SIGNATURE METHOD Sent to third party for signature
FILING INFORMATION
SUBMIT DATE Fri May 07 14:16:33 ET 2021
TEAS STAMP USPTO/ESU-XX.XXX.X.X-2021
0507141633708736-88155208
-78063637e9f981f306464952
89aded6f5d268d19b6c99c162
2a693ded5b3940135-CC-1630
0756-20210506142021180529



PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: INGREZZA (stylized and/or with design, see http://uspto.report/TM/88155208/mark.png)
SERIAL NUMBER: 88155208

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Neurocrine Biosciences, Inc., having an address of
      12780 El Camino Real
      San Diego, California 92130
      United States
      Email: XXXX
Proposed: Neurocrine Biosciences, Inc., having an address of
      12780 El Camino Real
      San Diego, California 92130
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 11/12/2019.

For International Class 005:
Current identification: Pharmaceutical preparations for human use for schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and Tourette syndrome, movement disorders, namely, Myoclonus, Huntington's chorea, Levodopa-induced dyskinesia, tardive dyskinesia, dystonia, and tics; Pharmaceutical preparations for the treatment of neurological, central nervous system, and movement diseases and disorders; Pharmaceutical preparations for the treatment of tardive dyskinesia

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

Correspondence Information (current):
      B. Brett Heavner
      PRIMARY EMAIL FOR CORRESPONDENCE: docketing@finnegan.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Correspondence Information (proposed):
      B. Brett Heavner
      PRIMARY EMAIL FOR CORRESPONDENCE: docketing@finnegan.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /David L. Bradfute/      Date Signed: 05/07/2021
Signatory's Name: David L. Bradfute, PhD, JD
Signatory's Position: Vice President & Head, Intellectual Property
Signatory's Phone: 202-408-4000 (Applicant's attorney)
Signature method: Sent to third party for signature

PAYMENT: 88155208
PAYMENT DATE: 05/07/2021

Serial Number: 88155208
Internet Transmission Date: Fri May 07 14:16:33 ET 2021
TEAS Stamp: USPTO/ESU-XX.XXX.X.X-2021050714163370873
6-88155208-78063637e9f981f30646495289ade
d6f5d268d19b6c99c1622a693ded5b3940135-CC
-16300756-20210506142021180529




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed